Natera Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Natera Inc 's ROA in the second quarter of 2026?
Natera Inc recorded a cumulative net loss of $-192 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -8.09%.

However, within the Healthcare sector 281 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3205, from total ROA ranking in the first quarter of 2026 at 3772.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	52.38 %	50.91 %	52.29 %	21.13 %	19.93 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-192	-226	-208	-309	-253
Return On Assets (TTM)	-8.09 %	-10.54 %	-10.8 %	-17.96 %	-15.42 %
NTRA's Total Ranking	# 3205	# 3772	# 3491	# 3452	# 3381
Total Assets (TTM) in million	2,677	2,614	2,398	1,821	1,757
Seq. Total Assets Change	2.41 %	9.01 %	31.67 %	3.67 %	1.43 %
Seq. Net Income Change	-	-	-	-	-

NTRA's 5 Years Annual ROA >> Back to NTRA Management Effectiveness >> Compare NTRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 17
Sector	# 282
Overall	# 3099

Return On Assets Statistics
High	Average	Low
-8.11 %	-37.11 %	-73.1 %
(Jun 30 2026)		(Dec 31 2017)

News about Natera Inc Return on Assets ROA

Nateras Signatera Test Joins Phase III ARCHER Trial in Bladder Cancer Amidst Financial Challenges

Natera Inc. (NASDAQ: NTRA), a leading entity in the realm of cell-free DNA and precision medicine, has announced a significant progression in its clinical research with the activation of the NRG Oncology trial, ARCHER (NRG-GU015). This landmark study aims to explore innovative treatment avenues in muscle-invasive bladder cancer (MIBC) by evaluating the efficacy of a shortened radiation course compared to the current standard of care.The ARCHER trial, now in its Phase III stage, represents a crucial step forward in the oncology field. Natera s Signatera test, renowned for its personalised, tumour-informed molecular residual disease (MRD) detection capabilities, has been incorporated into this study. By leveraging the strengths of Signatera, the trial intends to prospectively tailor treatments based on MRD insights, potentially offering patients a more precise and effective therapeutic regimen.

Nateras Breakthrough Colorectal Cancer Data Presented at ESMO Amid Ongoing Financial Challenges

At the recent European Society for Medical Oncology (ESMO) Congress in Barcelona, Natera, Inc. (NASDAQ: NTRA), unveiled promising results from its GALAXY study, a key segment of the ambitious CIRCULATE-Japan trial. This analysis marks a significant stride in colorectal cancer (CRC) research, specifically focused on the prospective application of circulating tumor DNA (ctDNA) testing in patients who have undergone surgical resection for the disease. The study is notable not only for its size and scope but also for its implications in predicting patient outcomes, with findings articulating Signatera s potential in forecasting overall survival rates among CRC patients.The GALAXY study reports data gathered from one of the largest and most comprehensive analyses of ctDNA testing in resectable CRC. This prospective research will provide invaluable insights, potentially helping oncologists make more informed decisions about treatment paths and patient monitoring post-surgery. The release of these findings at such a prestigious international platform underscores the growing recognition of ctDNA as a vital tool in personalized medicine and cancer management, fostering hope for improved patient prognoses.

Financial Statements
Natera Inc 's Assets	$ 2,677 million	NTRA's Balance sheet
Natera Inc 's Income	$ -67 million	Quarterly NTRA's Income Statement
NTRA's Income by Division		See NTRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	52.29 %	13.65 %	4.64 %	12.45 %	29.13 %
Total Assets in million	2,398	1,575	1,386	1,324	1,178
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-208	-190	-435	-548	-472
Annual Return On Assets	-8.68 %	-12.09 %	-31.38 %	-41.37 %	-40.06 %

NTRA's 5 Years Annual ROA >> Back to NTRA Management Effectiveness >> Compare NTRA ROA to its Competitors

More Return On Assets Ratios
NTRA's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NTRA's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NTRA's Competitors
Subscribers only: Roa for Natera Inc 's Suppliers
Subscribers only: Return On Assets for NTRA's Customers

You may also want to know
NTRA's Roi	NTRA's Inventory Turnover Ratio	NTRA's Growth Rates	NTRA's Dividend Comparisons
	NTRA's Profitability Ratios	NTRA's Asset Turnover Ratio	NTRA's Dividend Growth
NTRA's Roe	NTRA's Valuation Ratios	NTRA's Financial Strength Ratios	NTRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:20:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.